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Background: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed
colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation
fields and chemotherapy regimens.
Methods: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was
compared with general population rates. Treatment effects were quantified by Cox regression analyses.
Results: After a median follow-up of 22.9 years, 55 patients developed CRC. The standardized incidence ratios (SIR) was 2.4-fold
increased (95% confidence interval (95%CI) 1.8–3.2), leading to 5.7 excess cases per 10 000 patient-years. Risk was still increased 30
years after HL treatment (SIR: 2.8; 95%CI: 1.6–4.6). The highest (SIR: 6.5, 95%CI: 3.3–11.3) was seen for transverse colon cancer
(15.0 (95%CI: 4.3–40.8) after inverted-Y irradiation). A prescribed cumulative procarbazine dose44.2 gm 2 was associated with a
3.3-fold higher CRC risk (95%CI: 1.8–6.1) compared to treatment without procarbazine. Patients receiving 44.2 gm 2
procarbazine and infradiaphragmatic radiotherapy had a hazard ratio of 6.8 (95%CI: 3.0–15.6) compared with patients receiving
neither treatment, which is significantly higher than an additive joint effect (Padditivity¼ 0.004).
Conclusions: Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy
and a high cumulative procarbazine dose.
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Due to the introduction of multi-agent chemotherapy and the
continuing improvements in radiation techniques, Hodgkin
lymphoma (HL) has become the prototype of a curable
malignancy. Currently, the 10-year disease-specific survival is
more than 85% for patients diagnose before 55 years of age (IKNL,
2012). As a result of this favourable prognosis, there is a growing
population of HL survivors at risk of long-term complications
caused by radiation therapy and chemotherapy. The risk of solid
malignancies after HL treatment, especially risk of breast and lung
cancer, has been studied extensively (Swerdlow et al, 2000; van
Leeuwen et al, 2000; Dores et al, 2002; Ng et al, 2002; Travis et al,
2002; Travis et al, 2003; Hodgson et al, 2007; De Bruin et al, 2009;
van den Belt-Dusebout et al, 2009; Swerdlow et al, 2011; Reulen
et al, 2011; Swerdlow et al, 2012; Morton et al, 2013; Dores et al,
2014; Schaapveld et al, 2015). Although colorectal cancer (CRC) is
the third most common solid malignancy in HL survivors
(Hodgson et al, 2007; Schaapveld et al, 2015), so far few studies
have specifically examined risk factors for CRC after HL treatment
(Birdwell et al, 1997; Hodgson et al, 2007).
Colon and rectal cancers are often grouped together as they
share genetic and epidemiological features (Schottenfeld Winawer,
1982; Network, 2012). Among Japanese atomic bomb survivors
increased risk of colon, but not rectum cancer, emerged from 10
years after exposure (Nakatsuka et al, 1992; Nakachi et al, 2006;
Preston et al, 2007). Excess rectum cancer risk was found after
exposure to higher radiation doses (Land, 1986). Although in
atomic bomb survivors, colon subsites showed equal sensitivity to
radiation (Nakatsuka et al, 1992); studies of CRC risk among
medically-irradiated subjects are complicated by the fact that the
colon extends over a large part of the abdomen, and depending
upon the radiation techniques, may receive markedly non-uniform
doses. Surprisingly, CRC risk has not previously been assessed
specifically for colorectal subsites.
Procarbazine has been shown to increase the risk of stomach
(van den Belt-Dusebout et al, 2009; Morton et al, 2013) and lung
cancer (Swerdlow et al, 2001; Travis et al, 2002) in HL patients.
Although Morton and colleagues found statistically significant
associations of stomach cancer risk with exposure to procarbazine
or dacarbazine but not with other alkylating agents, in the study by
Travis and colleagues lung cancer risk was associated both with
exposure to mechlorethamine or procarbazine. It is unknown
whether chemotherapy also affects CRC risk among HL survivors.
However, alkylating agent exposure was associated with an 8.8-fold
increased risk of CRC among childhood cancer survivors (9 out of
19 CRC diagnosed in childhood HL survivors) treated at St Jude
Children’s Research Hospital (Nottage et al, 2012). Similarly,
Henderson and colleagues previously reported that procarbazine
independently increased risk, potentially in a dose–response
manner, of gastrointestinal malignancies in childhood cancer
survivors treated with abdominal irradiation (Henderson et al,
2012). Of note, out of 45 gastrointestinal malignancies, 20 were
diagnosed among HL survivors and 24 were colorectal cancers. In
this study, we therefore assessed the long-term subsite-specific risk
of CRC after HL treatment, taking into account radiation fields and
cumulative dose of alkylating agents, in a large multicenter Dutch
cohort comprising 3121 5-year survivors of HL.
PATIENTS AND METHODS
Our cohort comprised of HL patients treated in seven Dutch
University Hospitals or Cancer Centers and in the affiliated
hospitals of the former population-based Eindhoven Cancer
Registry. Patient selection and the data collection methods have
been described in detail previously (van Leeuwen et al, 2000;
De Bruin et al, 2009; Schaapveld et al, 2015). Briefly, patients were
younger than 51 years at HL treatment (range: 3.6–50.9), first
treated between 1965 and 1995 with radiation therapy and/or
chemotherapy, and survived at least 5 years. The detailed treatment
data (dates of start of treatment, radiation fields, chemotherapy
regimens and number of cycles) were collected from the medical
records, both for initial and relapse treatment. Up to 2004 data on
second malignancy diagnoses was obtained from the medical
records and by contacting general practitioners and attending
physicians in other hospitals (94% complete follow-up) (De Bruin
et al, 2009). Additionally, CRCs diagnoses between 2004 and
January 2011 were ascertained through linkage with the nation-
wide PALGA network and registry of histo- and cytopathology
(Casparie et al, 2007) and the Netherlands Cancer Registry (NCR).
PALGA reached nation-wide coverage in January 1990 and the
NCR in January 1989. Completeness of case ascertainment by the
NCR is 498% (Schouten et al, 1994).
Colorectal cancers were classified according to the International
Classification of Diseases for Oncology (ICD-O-3) (WHO, 2000).
Colorectal cancers were categorised into ascending colon (includ-
ing coecum and hepatic flexure), transverse colon (including
splenic flexure), descending colon (including sigmoid colon), and
rectum (including rectosigmoid junction). Each CRC was classified
as ‘in field’, ‘out of field’ or ‘unknown’ based on review of the
radiation fields by a radiation oncologist (BMPA). Vital status was
obtained up to January 2011 through linkage with the Dutch
Central Bureau of Genealogy; 2.7% of the patients had either
emigrated or were otherwise lost-to-follow-up.
Treatment. Over time a wide variety of treatment regimens was
used in the cohort. Although primary treatment was usually given
in accordance with treatment protocols of the European Organisa-
tion for Research and Treatment of Cancer (Favier et al, 2009)
treatment for recurrences was generally not standardised. Patients
usually received 40Gy in 20 fractions when treated with radiation
therapy only and 30–36Gy in 15–20 fractions when they also
received chemotherapy. Mantle field irradiation (mediastinal,
axillary and neck nodes) was the most commonly applied radiation
field from the early 1970s to the late 1980s. Infradiaphragmatic
radiation, commonly including the para-aortic nodes and spleen
(para-aortal field), but frequently also the iliac and inguinal nodes
(inverted Y field), was given until the late 1980s as part of
(sub)total nodal irradiation (Supplementary Figure 1). Since the
late 1980s, a growing number of patients received more limited
radiation fields. Information on radiation doses and fractionation
schedules for individual patients was not routinely collected for all
participating hospitals. From the late 1960s to the 1980s,
chemotherapy consisted mainly of MOPP (mechlorethamine,
vincristine, procarbazine, prednisone). In the 1980s, anthracy-
cline-containing regimens such as MOPP/ABV (mechlorethamine,
vincristine, procarbazine, prednisone/doxorubicin, bleomycin,
vinblastine) and ABVD (doxorubicin, bleomycin, vinblastine,
dacarbazine) were introduced.
Statistical analysis. Colorectal cancer incidence in the cohort was
compared with age-, sex-, subsite and calendar period-specific CRC
incidence rates in the Dutch population, accounting for person-
years of observation. The cancer incidence data from the
Eindhoven Cancer Registry up to 1988 and from the Netherlands
Cancer Registry from 1989 onwards were used as reference (IKNL,
2012).
Time at risk began 5 years after the start of HL treatment and
ended at the date of CRC diagnosis, date of death or date of most
recent medical information, whichever came first. HL was the first
primary malignancy in all patients. Patients who developed a
subsequent malignancy within 5-years after HL were excluded. All
CRC diagnosedX5 years after start of HL treatment were retained
in the analyses. Standardized incidence ratios (SIRs) were
calculated as the ratios of the observed and expected numbers of
Colorectal cancer after Hodgkin lymphoma BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.177 307
CRC in the cohort, and absolute excess risks (AERs) as the
observed numbers of CRC in our cohort minus the expected
numbers, divided by number of person-years at risk, multiplied by
10 000. Standardized incidence ratios were calculated for any CRC
and for colon cancer subsites and rectal cancer separately; analyses
were performed by sex, age at first HL treatment, follow-up
interval, and type of treatment. Prescribed cumulative procarbazine
doses were estimated using standard procarbazine doses per cycle
in each chemotherapy regimen as a measure for alkylating
chemotherapy dose; that is, three cycles of MOPP or six cycles
of MOPP-ABV are equivalent to a prescribed cumulative
procarbazine dose of 4.2 gm 2 of body surface area. For 172
patients (7.9% of chemotherapy-treated patients), the prescribed
procarbazine dose was unknown. A multivariate single mean
imputation approach was applied to account for missing
procarbazine doses, under the missing at random assumption,
using a multinomial logistic regression model. Variables used for
imputation were sex, age, year and hospital at HL treatment, type
of chemotherapy and number of cycles, and CRC occurrence (yes/
no). Confidence intervals for SIRs and tests for homogeneity and
trend of SIRs were calculated using standard methods (Breslow
Day, 1987).
The cumulative incidence of CRC was estimated in the presence
of death as a competing risk. Multivariable Cox regression analyses
were performed to quantify the effects of HL treatment on CRC risk
with time since start of HL treatment as time-scale. The proportional
hazard assumption was assessed using residual-based methods.
Variables considered in this analysis were sex, age and HL treatment.
Interaction between a procarbazine dose 44.2 gm 2 and infra-
diaphragmatic radiation was assessed by evaluating departure from
an additive model HR¼ 1þ (1procarbazineþ 2infraRT)
exp(3(procarbazineþ infraRT)) or from a multiplicative model HR¼
exp(1procarbazineþ 2infraRTþ 3(procarbazineþ infraRT)), that is, by testing
whether 3¼ 0 using a likelihood ratio test. Analyses were
performed using STATA (STATA 13, Statacorp LP, College Station,
TX, USA) and Epicure statistical software (Epicure, version 1.8,
Hirosoft International, Seattle, WA, USA). A P-value o0.05 was
considered statistically significant.
RESULTS
Patient characteristics. Median age at start of HL treatment was
27.3 years (interquartile range (IQR) 21.0–35.5; Table 1). Almost
50% had received infradiaphragmatic radiation therapy; 28%
received chemotherapy and infradiaphragmatic radiation therapy
combined. Chemotherapy mostly comprised of MOPP or MOPP-
like chemotherapy; 35.8% of the patients treated with chemother-
apy received 44.2 gm 2 procarbazine-containing chemotherapy.
Median follow-up was 22.9 years (IQR 16.7–30.7) and 23.4% of
patients were followed X30 years.
Fifty-five HL survivors developed CRC; 34 patients had colon
cancer and 21 rectal cancer. Among the 52 CRC patients treated
with radiation therapy, the CRC was located within the radiation
field in 46% and outside in 42%; for 12% this was unknown
(Supplementary Table 1). The median time to CRC diagnosis was
22.9 years (IQR: 16.7–30.7) and median age at CRC diagnosis was
56.4 years (IQR: 50.6–62.2; Table 1). The youngest CRC patient
was 35 years at diagnosis. Most CRCs were stage 2 (38%) or higher
(stage 3 (24%) and stage 4 (15%); Supplementary Table 1). At the
end of follow-up, 43 CRC patients had died, of whom 17 (40%) due
to CRC. The 5-year overall survival after CRC diagnosis was 31%.
CRC risk compared with the general population. HL survivors
had a 2.4-fold (95% confidence interval (CI) 1.8–3.2) increased SIR
of developing CRC compared with the general population,
corresponding to 5.7 excess cases per 10 000 patient-years
Table 1. General characteristics of all Hodgkin lymphoma
patients and colorectal cancer (CRC) patients
Cohort % CRC cases %
All patients 3121 100.0 55 100.0
Sex
Men 1776 56.9 34 61.8
Women 1345 43.1 21 38.2
Age at first HL treatment (years)
Median (IQR) 27.3
(21.0–35.5)
30.4
(23.4–41.8)
o25a 1284 41.2 17 30.9
25–34 1009 32.3 16 29.1
35–50 828 26.5 22 40.0
Stage HL
I 719 23.0 12 21.8
II 1398 44.8 15 27.3
III & IV 795 25.5 16 29.1
Unknown 209 6.7 12 21.8
Treatment period
1965–1974 660 21.1 25 45.5
1975–1984 1045 33.5 23 41.8
1985–1995 1416 45.4 7 12.7
Follow-up (years)
Median (IQR) 22.9
(16.7–30.7)
22.9
(16.7–30.7)
5–9 304 9.8 2 3.6
10–19 869 27.8 16 29.1
20–29 1218 39.0 21 38.2
X30 730 23.4 16 29.1
Treatment for HL
Treatment categoryb
CT only 318 10.2 3 5.5
Supradiaphragmatic RT, no CT 342 11.0 3 5.5
Supradiaphragmatic RTþCT 983 31.5 13 23.6
Infra-±supradiaphragmatic RT, no CT 599 19.2 9 16.3
Infra-±supradiaphragmatic RTþCT 879 28.1 27 49.1
Infradiaphragmatic irradiationb
No infradiaphragmatic RTc 1643 52.6 19 34.6
PAO 321 10.3 6 10.9
PAOþ spleen 619 19.8 8 14.6
Inverted Yd±spleen 423 13.6 18 32.7
Infradiaphragmatic othere 115 3.7 4 7.2
CT regimenb
No CT 940 30.1 12 21.8
MOPP or MOPP-likef 914 29.3 28 50.9
MOPP and ABVD 152 4.9 2 3.6
MOPP and ABV 577 18.5 4 7.3
EBVP 61 1.9 0 0
ABVD 101 3.2 0 0
Otherg 376 12.1 9 16.4
CT treatment according to cumulative
procarbazine doseh,b
No CT 940 30.1 12 21.8
Non-alkylating CT only 147 4.7 3 5.5
Alkylating CT, no procarbazine 169 5.4 1 1.8
Alkylating CT, r4.2gm 2
procarbazine
577 18.5 5 9.1
Alkylating CT, 44.2–8.4gm 2
procarbazine
684 21.9 17 30.9
Alkylating CT, 48.4gm 2
procarbazine
433 13.9 14 25.4
CT, type unknown 171 5.5 3 5.5
Age at CRC diagnosis (years)
Median (IQR) — — 56.4 (50.6–62.2)
Abbreviations: ABVD¼doxorubicin, bleomycin, vinblastine, dacarbazine; CRC¼ colorectal
cancer; CT¼ chemotherapy; EBVP¼ epirubicine, bleomycin, vinblastine, prednisone; HL¼
Hodgkin lymphoma; MOPP¼mechlorethamine, vincristine, procarbazine, prednisone; MOPP-
ABV(D)¼ mechlorethamine, vincristine, procarbazine, prednisone – doxorubicin, bleomycin,
vinblastine, (dacarbazine); PAO¼para-aortic; IQR¼ inter quartile range; RT¼ radiation therapy.
aIn all, 218 patients (7.0%) were younger than 15 years at HL diagnosis.
bIncluded primary and relapse therapy. RT includes all radiation fields.
cNo RT or supradiaphragmatic RT only.
dInverted Y field consists of para-aortic and iliac nodes.
eInclude iliacal and inguinal fields.
fMOPP-like regimens include at least procarbazine, e.g. CVPP-LO, COPP, CHOPP, MVPP, LOPP.
gIncludes single agents, other CT regimens, and CT agent unknown.
hMutually exclusive categories.
BRITISH JOURNAL OF CANCER Colorectal cancer after Hodgkin lymphoma
308 www.bjcancer.com |DOI:10.1038/bjc.2017.177
(Table 2). The SIRs of rectal and colon cancer were 2.4 (95%CI:
1.5–3.7) and 2.5 (95% CI: 1.7–3.4), respectively. While risks of
transverse colon (SIR: 6.5; 95%CI: 3.3–11.3) and ascending colon
cancer (SIR: 2.2; 95%CI: 1.1–3.8) were increased, the risk of
descending colon cancer was not (SIR: 1.2, 95%CI: 0.5–2.4). The
SIR was slightly higher in men (SIR: 3.2, 95% CI: 2.2–4.4) than in
women (SIR: 1.8, 95% CI: 1.1–2.7; p-heterogeneity: 0.04).
Colorectal cancer risk by age at first and time since HL
treatment. The SIR of CRC was highest for patients treated o25
years of age (SIR: 4.9; 95%CI: 2.8–7.8 compared to 1.8; 95%CI:
1.1–2.8, for patients 35–50 years; p-trend 0.004, Table 3). However,
while for colon cancer, the SIRs decreased with older age at HL
treatment (SIRs were 6.8 and 1.3 for patients treated o25 years
or at age 35–50 years, respectively; p-trend o0.001), this was
not the case for rectal cancer (SIRs were 2.1 and 2.6 for patients
treated o25 years or at age 35–50 years, respectively; p-trend
0.90).
The SIR of CRC was elevated from 10 years after treatment and
remained increased with longer follow-up duration, with SIRs of
2.3 (95%CI: 1.3–3.7) at 10–19 years and 2.8 (95%CI: 1.6–4.6) at
Z30 years of follow-up (p-trend¼ 0.29). The AER of CRC
increased steadily with longer follow-up duration
(p-trendo0.001); the AER was 3.6 at 10–19 years and 24.6 per
10 000 patients-years at X30 years of follow-up, respectively (data
not shown).
Table 2. Risk of colorectal cancer after HL treatment: SIR, AER, and 20-year and 30-year cumulative incidence
Cases SIR (95%CI) AER (95%CI)
20-year cumulative
incidence (%)a
30-year cumulative
incidence (%)a
Tumour siteb
Colorectal 55 2.4 (1.8–3.2) 5.7 (3.3–8.6) 0.6 (0.4–1.0) 2.1 (1.4–2.8)
Colon 34 2.5 (1.7–3.4) 3.5 (1.7–5.9) 0.3 (0.1–0.5) 1.2 (0.8–1.9)
Ascending colon 12 2.2 (1.1–3.8) 1.1 (0.1–2.7) 0.1 (0.0–0.2) 0.4 (0.2–0.8)
Transverse colon 12 6.5 (3.3–11.3) 1.8 (0.8–3.4) 0.1 (0.0–0.3) 0.5 (0.2–0.9)
Descending colon 8 1.2 (0.5–2.4) 0.3 (-0.5–1.6) 0.1 (0.0–0.3) 0.3 (0.1–0.6)
Colon, NOS 2 4.3 (0.5–15.4) 0.3 (0.0–1.2) — 0.1 (0.0–0.5)
Rectum 21 2.4 (1.5–3.7) 2.1 (0.7–4.1) 0.4 (0.2–0.6) 0.8 (0.5–1.0)
Sex
Men 34 3.2 (2.2–4.4) 7.4 (4.1–11.8) 0.7 (0.4–1.2) 2.0 (1.3–3.0)
Women 21 1.8 (1.1–2.7) 3.6 (0.5–7.9) 0.6 (0.3–1.1) 2.1 (1.2–3.5)
P-heterogeneity 0.04 0.13
Age at first HL treatment (years)
o25 17 4.9 (2.8–7.8) 5.2 (2.5–9.2) 0.2 (0.1–0.7) 1.1 (0.5–2.1)
25–34 16 2.3 (1.3–3.7) 4.9 (1.2–10.3) 0.2 (0.0–0.7) 2.5 (1.3–4.3)
35–50 22 1.8 (1.1–2.8) 7.8 (1.3–16.8) 1.9 (1.0–3.1) 3.3 (1.9–5.4)
P-trend 0.004 0.62
Treatment for HL
Treatment categoryc
CT only 3 1.1 (0.2–3.3) 0.6 (-3.3–10.1) 0.3 (0.0–1.7) 0.8 (0.2–2.7)
Supradiaphragmatic RT, no CT 3 0.9 (0.2–2.6)  0.4 (-3.6–7.2) 0.3 (0.0–1.6) 0.9 (0.2–3.3)
Supradiaphragmatic RTþCT 13 2.0 (1.0–3.3) 3.6 (0.2–8.9) 0.3 (0.1–0.9) 1.7 (0.8–3.4)
Infra-±supradiaphragmatic RT, no CT 9 1.8 (0.8–3.3) 3.3 ( 0.9–10.1) 0.8 (0.3–1.8) 2.0 (0.8–4.2)
Infra-±supradiaphragmatic RTþCT 27 5.7 (3.7–8.2) 15.9 (9.3–24.7) 1.2 (0.6–2.1) 3.4 (2.0–5.2)
P-heterogeneity o0.001 o0.001
Infradiaphragmatic irradiationc
No infradiaphragmatic RTd 19 1.5 (0.9–2.3) 2.0 (-0.4–5.4) 0.3 (0.1–0.7) 1.4 (0.7–2.4)
PAO 6 2.2 (0.8–4.8) 4.9 (-0.8–15.6) 0.7 (0.1–2.3) 2.2 (0.9–4.8)
PAOþ spleen 8 2.2 (1.0–4.4) 4.3 (-0.1–11.9) 0.7 (0.2–1.7) 1.3 (0.5–2.7)
Inverted Ye±spleen 18 6.1 (3.6–9.6) 21.1 (10.8–35.8) 1.6 (0.7–3.3) 4.2 (2.2–7.1)
Infradiaphragmatic otherf 4 6.3 (1.7–16.2) 18.1 (2.5–51.6) 1.0 (0.1–4.9) 4.4 (1.1–11.6)
P-heterogenity o0.001 0.02
CT treatment (according to cumulative
procarbazine dose)g,c
No CT 12 1.4 (0.7–2.5) 1.8 ( 1.2–6.4) 0.6 (0.2–1.3) 1.6 (0.7–3.0)
Non-alkylating CT only 3 1.6 (0.3–4.8) 3.6 ( 3.8–21.6)  2.3 (0.4–7.6)
Alkylating CT, no procarbazine 1 0.8 (0.0–4.5)  0.8 (-3.9–13.8)  3.1 (0.2–13.4)
Alkylating CT,p4.2 gm2 procarbazine 5 1.8 (0.6–4.1) 2.5 ( 1.4–10.1) 0.8 (0.3–1.8) 2.0 (0.5–5.7)
Alkylating CT, 4.2–8.4 gm 2 procarbazine 17 3.7 (2.6–5.9) 9.8 (4.2–17.9) 0.9 (0.4–2.0) 1.8 (0.9–3.2)
Alkylating CT,48.4 gm2 procarbazine 14 5.2 (2.9–8.8) 16.2 (7.1–29.9) 0.5 (0.1–1.8) 3.4 (1.7–5.9)
CT, type unknown 3 3.5 (0.7–10.2) 7.0 (-0.8–25.9) 0.6 (0.1–3.1) 1.6 (0.3–5.1)
P-heterogeneity 0.01 0.05
Abbreviations: 95% CI¼ 95% confidence interval; ABVD¼ doxorubicin, bleomycin, vinblastine, dacarbazine; AER ¼ absolute excess risk per 10 000 person-years; CRC¼ colorectal cancer;
CT¼ chemotherapy; EBVP¼epirubicine, bleomycin, vinblastine, prednisone; PAO¼para-aortic; HL¼Hodgkin lymphoma; MOPP¼mechlorethamine, vincristine, procarbazine, prednisone;
MOPP-ABV(D)¼mechlorethamine, vincristine, procarbazine, prednisone – doxorubicin, bleomycin, vinblastine, (dacarbazine); n.a.¼not applicable; NOS¼ not otherwise specified;
SIR¼ Standardized Incidence Ratio; RT¼ radiation therapy.
aTotal number at risk at 20 years: 1948, total number at risk at 30 years: 730.
bColon subsites were categorised as ascending colon (plus cecum and hepatic flexura), transverse colon (plus splenic flexura), and descending colon (plus (recto)sigmoid).
cIncluded primary and relapse therapy. RT includes all radiotherapy fields.
dNo RT or supradiaphragmatic RT only.
eInverted Y field consists of para-aortic and iliac nodes.
fInclude iliacal and inguinal fields.
gMutually exclusive categories.
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Treatment-specific CRC risk compared to the general popula-
tion. The SIR of CRC was not increased in patients treated with
chemotherapy only or supradiaphragmatic radiation therapy only
(Table 2). Patients treated with supradiaphragmatic radiation
therapy and chemotherapy had a 2.0-fold increased CRC risk
(95%CI: 1.0–3.3). Infradiaphragmatically irradiated patients not
treated with chemotherapy had a nonsignificantly increased risk of
CRC (SIR: 1.8, 95%CI: 0.8–3.3). The highest SIR of CRC was
observed in patients who received infradiaphragmatic radiation
therapy and chemotherapy (SIR: 5.7, 95%CI: 3.7–8.2), translating
into an AER of 15.9 per 10 000 patient-years. Patients treated with
para-aortic fields had a 3.0-fold increased (95%CI: 1.0–7.1) risk of
colon cancer. Risk of transverse colon cancer was even 15.9-fold
increased (95%CI: 4.3–40.8) after treatment with an inverted-Y
field (Table 3). The highest SIR of rectal cancer was observed
following treatment with inverted-Y fields (SIR: 6.3, 95%CI: 2.5–
13.0). Patients treated with 44.2 gm 2 procarbazine had a
strongly increased risk of developing CRC compared with the
general population (SIR: 4.3, 95%CI: 2.9–6.1).
Risk factors for CRC: multivariable regression analysis. In
multivariable Cox analyses (Table 4), infradiaphragmatic radiation
therapy was associated with increased CRC risk (age- and sex-
adjusted hazard ratio (HR) 2.8, 95%CI: 1.6–4.9). Patients treated with
a procarbazine dose 44.2 gm 2 also had an increased CRC-risk
(HR: 3.3, 95%CI: 1.8–6.2) compared to patients receiving
p4.2 gm 2 of procarbazine. A very high CRC risk was seen for
patients who had received both a procarbazine dose44.2 gm 2 and
infradiaphragmatic radiation therapy (HR: 6.8, 95%CI:
3.0–15.6, compared with patients receiving none of these treatments).
The combined effect of prescribed procarbazine dose and infra-
diaphragmatic radiation therapy showed departure from additivity
(padditivity¼ 0.0043), pointing to a synergistic effect of procarbazine
and infradiaphragmatic radiation therapy. The data did not support a
supermultiplicative joint effect (pmultiplicativity¼ 0.153). This com-
bined effect of a prescribed procarbazine dose 44.2 gm 2 and
infradiaphragmatic radiation therapy was stronger for transverse
colon and rectal cancer, which were more often located in the
radiation fields (HR: 10.1, 95%CI: 3.3–30.7).
Table 3. Risks of colorectal cancer after HL treatment; SIRs by sex, age, follow-up interval and treatment
All colon sites (n¼34) Transverse colona (n¼12) Colon otherb (n¼22) Rectum (n¼21)
Tumour site O SIR 95% CI O SIR 95% CI O SIR 95% CI O SIR 95% CI
Risk factor
Sex
Men 23 3.3 2.1–5.0 8 8.5 3.7–16.7 15 2.4 1.4–4.0 11 2.9 1.5–5.2
Women 11 1.6 0.8–2.9 4 4.4 1.2–11.2 7 1.1 0.5–2.3 10 2.0 1.0–3.7
Age at first HL treatment (years)
o25 14 6.8 3.7–11.3 6 19.3 7.1–42.0 8 4.2 1.8–8.2 3 2.1 0.4–6.1
25–34 10 2.4 1.2–4.4 3 5.3 1.1–15.6 7 1.9 0.7–3.8 6 2.2 0.8–4.7
35–50 10 1.3 0.6–2.4 3 3.1 0.6–18.9 7 1.0 0.4–2.2 12 2.6 1.4–4.6
Follow-up period (years)
5–9 1 1.0 0.0–5.3 0 — — 1 0.9 0.0–5.2 1 1.4 0.0–7.9
10–19 7 1.7 0.7–3.4 4 6.7 1.8–17.3 3 0.8 0.2–2.3 9 3.2 1.5–6.1
20–29 14 2.8 1.5–4.7 5 8.1 2.6–18.9 9 2.1 0.9–3.9 7 2.2 0.9–4.6
X30 12 3.4 1.7–5.9 3 7.0 1.4–20.4 9 2.9 1.3–5.4 4 1.9 0.5–4.9
Treatment for HLc
Treatment categoryc
CT only 1 0.6 0.0–3.4 0 — — 1 0.7 0.0–3.8 2 2.0 0.2–7.3
Supradiaphragmatic RT, no CT 2 1.0 0.1–3.5 1 3.5 0.1–19.5 1 0.5 0.0–3.0 1 0.8 0.0–4.3
Supradiaphragmatic RTþCT 8 2.0 0.9–3.9 1 1.9 0.0–10.4 7 1.9 0.8–4.0 5 1.9 0.6–4.5
Infra-±supradiaphragmatic RT, no CT 7 2.2 0.9–4.6 2 4.9 0.6–17.6 5 1.8 0.6–4.2 2 1.0 0.1–3.6
Infra-±supradiaphragmatic RTþCT 16 5.5 3.1–8.9 8 19.6 8.5–38.6 8 3.0 1.3–6.0 11 5.9 2.9–10.5
Infradiaphragmatic irradiationc
No infradiaphragmatic RTd 11 1.4 0.7–2.5 2 1.9 0.2–7.0 9 1.3 0.6–2.5 8 1.6 0.7–3.2
PAO 5 3.0 1.0–7.1 2 8.8 1.1–32.0 3 2.0 0.4–5.8 1 0.9 0.0–5.2
PAOþ spleen 5 2.3 0.8–5.4 4 14.0 3.8–35.8 1 0.5 0.0–2.9 3 2.1 0.4–6.1
Inverted Ye±spleen 11 6.0 3.0–10.7 4 15.9 4.3–40.8 7 4.2 1.7–8.7 7 6.3 2.5–13.0
Infradiaphragmatic other 2 5.2 0.6–18.9 — — — 2 5.7 0.7–20.7 2 8.1 1.0–29.1
CT treatment according to cumulative
procarbazine dosec,f
No CT 9 1.7 0.8–3.3 3 4.3 0.9–12.6 6 1.3 0.5–2.8 3 0.9 0.2–2.7
Non-alkylating CT only 2 1.8 0.2–6.4 0 — — 2 2.0 0.2–7.1 1 1.4 0.0–8.0
Alkylating CT, no procarbazine 0 — — 0 — — 0 — — 1 2.0 0.1–11.4
Alkylating CT,p4.2gm 2 procarbazine 3 1.7 0.4–5.1 1 4.4 0.1–24.7 2 1.3 0.2–4.7 2 1.8 0.2–6.4
Alkylating CT, 4.2–8.4 gm 2 procarbazine 7 2.5 1.0–5.2 2 5.4 0.7–19.5 5 2.0 0.6–4.6 10 5.6 2.7–10.3
Alkylating CT,48.4gm 2 procarbazine 10 6.1 2.9–11.2 5 21.9 7.1–51.0 5 3.3 1.1–7.8 4 3.9 1.1–9.9
CT, type unknown 3 5.6 1.2–16.4 1 13.3 0.3–74.2 2 4.1 0.5–14.8 0 — —
Alkylating CT,44.2gm 2 procarbazine 17 3.8 2.2–6.1 7 11.7 4.7–24.1 10 2.5 1.2–4.8 14 5.0 2.7–8.3
Abbreviations: 95% CI¼ 95% confidence interval; ABVD¼ doxorubicin, bleomycin, vinblastine, dacarbazine ; AER ¼ absolute excess risk per 10000 person-years; Colon other¼ ascending colon,
descending colon, colon not otherwise specified; CT¼ chemotherapy; EBVP¼epirubicine, bleomycin, vinblastine, prednisone; MOPP¼mechlorethamine, vincristine, procarbazine, prednisone;
MOPP-ABV(D)¼ mechlorethamine, vincristine, procarbazine, prednisone—doxorubicin, bleomycin, vinblastine, dacarbazine; O¼Observed number; PAO¼para-aortic; RT¼ radiation therapy;
SIR¼ Standardized Incidence Ratio.
aIncludes transverse colon and splenic flexura.
bIncludes ascending colon, cecum, hepatic flexura and descending colon.
cIncluded primary and relapse therapy. RT includes all radiotherapy fields.
dNo RT and supradiaphragmatic RT.
eInverted Y field consists of para-aortic and iliac nodes.
fMutually exclusive categories.
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Cumulative incidence of CRC. The cumulative incidence of any
CRC was 0.6% (95%CI: 0.4–1.0) at 20 years and 2.1% (95%CI: 1.4–
2.8) at 30 years of follow-up (Table 2). Although, compared to
younger patients, patients aged 35–50 years at HL treatment had a
higher cumulative incidence of CRC throughout follow-up (30-
year cumulative incidence 2.7%, 95%CI: 1.6–4.3%), their cumula-
tive incidence did not differ much from the population expected
CRC incidence (expected 30-year cumulative incidence of 2.7%). In
contrast, the cumulative CRC incidence among patientso25 years
at HL treatment was much higher than the population-expected
CRC incidence throughout follow-up; the 30-year observed
cumulative incidence was 1.0% (95%CI: 0.5–1.9%) compared to
an expected cumulative incidence of 0.2% (Supplementary
Figure 2). The 30-year cumulative incidence was 1.2% (95%CI:
0.8–1.9) for colon cancer and 0.8% (95%CI: 0.5–1.0) for rectal
cancer. At the age of 55 years, currently the starting age for
colorectal cancer screening in the Dutch population, the cumula-
tive incidence of CRC was 2.4% (95%CI: 1.3–4.1%) for patients
treated for HL o25 years of age, compared to an expected
cumulative incidence of 0.6% assuming similar CRC rates as in the
general population (Figure 1A). Hodgkin survivors treated for HL
o25 years of age reached a cumulative incidence of 0.6% at 46.5
years of age. The cumulative incidence of CRC was 0.9% (95%CI:
0.4–1.8%) for patients treated for HL at age 25–34 years. For
patients treated for HL before age 35 with both infradiaphragmatic
radiation therapy and chemotherapy with a procarbazine dose
44.2 gm 2, the cumulative incidence of CRC was 4.2% (95%CI:
2.3–7.1%) at the age of 55 years, compared to a general population
expected cumulative incidence at age 55 years of 0.6% (Figure 1B).
These HL patients already reached a cumulative incidence of 0.6%
at an attained age of 38 years.
DISCUSSION
To the best of our knowledge, this is the first study that assessed
long-term subsite-specific CRC-risk after HL treatment in a large
multicenter cohort of HL survivors. In our study, HL survivors had
a 2.4-fold increased risk to develop CRC compared to the general
population; risk was highest for cancer of the transverse colon. The
increased CRC risk emerged late and the risk was still increased
X30 years after first treatment. An inverted-Y field with/without
spleen irradiation was associated with a 15.9-fold increased risk of
transverse colon cancer and a 6.3-fold increased risk of rectal
cancer. Our most important and novel finding is that CRC risk was
especially increased in patients who had received both high-dose
procarbazine and infradiaphragmatic radiation therapy (HR: 6.8,
95%CI: 3.0–15.6). This association was stronger for colorectal
subsites, which were more likely exposed to higher radiation doses
such as the transverse colon and rectum.
In the general population, colon cancer is most often located in
the ascending and descending colon (Lemmens et al, 2010). While
12% of all colon cancers in the general population are located in
the transverse colon (IKNL, 2012), in our population, 35.3% (12
out of 34) of CRCs were located in the transverse colon. Likely, this
is due to the fact that the transverse colon receives a high radiation
dose in standard infradiaphragmatic fields. In the atomic bomb
survivors, who received whole body irradiation, the colon cancers
subsite distribution did not differ by radiation dose, indicating that
the different subsites of the colon seem equally sensitive to
radiation (Nakatsuka et al, 1992). In a study by Henderson and
colleagues (Henderson et al, 2012), evaluating gastrointestinal
cancer risk among childhood cancer survivors, 82% of the
gastrointestinal cancers were in or near the radiation fields. In
line with our results, Nottage and colleagues also reported that
among childhood cancer survivors second CRCs were more likely
to develop in the irradiated segments of the colon (Nottage et al,
2012).
Exposure to alkylating agents, such as procarbazine, has been
shown to increase the risk of several solid tumours in humans
(Swerdlow et al, 2001; Travis et al, 2002; van den Belt-Dusebout
et al, 2009; Morton et al, 2013; Dores et al, 2014). Our group
previously reported increasing stomach cancer risk with higher
doses of procarbazine in HL survivors, which was confirmed in a
larger international study (van den Belt-Dusebout et al, 2009;
Table 4. Treatment-related risk factors for the occurrence of colorectal cancer during follow-up: multivariable Cox regression
analysis
Cohort CRC Transverse colon and rectum
Risk factor Total Cases HR 95% CI Cases HR 95% CI
Treatment
Model Ia
Procarbazine
No CT or CT without procarbazine 1256 16 1.00 Reference 8 1.00 Reference
CT, r4.2 gm 2 procarbazine 577 5 1.4 0.5–3.7 3 1.5 0.4–5.6
CT, 44.2 gm2 procarbazine 1117 31 3.3 1.8–6.1 21 4.8 2.1–10.9
P-trendb o0.001 o0.001
Radiotherapy
No infradiaphragmatic RT 1643 19 1.00 Reference 10 1.00 Reference
Infradiaphragmatic RT 1478 36 2.8 1.6–4.9 23 3.5 1.7–7.5
P-trendb o0.001 o0.001
Model IIa,c,d
Procarbazine and radiotherapy
No infradiaphragmatic RT, r4.2 gm 2 procarbazine 911 8 1.00 Reference 4 1.00 Reference
No infradiaphragmatic RT, 44.2 gm2 procarbazine 632 10 1.8 0.7–4.5 6 2.1 0.6–7.5
Infradiaphragmatic RT, r4.2 gm 2 procarbazine 922 13 1.7 0.7–4.0 7 1.7 0.5–5.8
Infradiaphragmatic RT, 44.2gm2 procarbazine 485 21 6.8 3.0–15.6 15 10.1 3.3–30.7
P-heterogeneityb o0.001 o0.001
Abbreviations: 95% CI¼ 95% confidence interval; CRC¼ colorectal cancer; CT¼ chemotherapy; HR¼ hazard ratio; RT¼ radiation therapy.
aAdjusted for age at HL diagnosis (continuously) and sex using time since diagnosis as time-scale. HRs for missing procarbazine dose not shown.
bP-values based on Likelihood ratio tests.
cJoint effect of procarbazine and radiotherapy for CRC: P-additivity¼ 0.0043; P-multiplicativity¼ 0.153.
dJoint effect of procarbazine and radiotherapy for transverse colon & rectum: P-additivity¼ 0.0041; P-multiplicativity¼ 0.199.
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Morton et al, 2013). Nottage and colleagues observed that
alkylating agent exposure was associated with an almost nine-fold
increased risk of CRC; associations with specific agents were not
reported (Nottage et al, 2012). In the study by Henderson and
colleagues, high-dose procarbazine exposure was independently
associated with an increased risk of gastrointestinal malignancies in
childhood cancer survivors treated with abdominal radiation, while
exposure to procarbazine without abdominal radiation was not
associated with gastrointestinal malignancies (Henderson et al,
2012).
Because procarbazine and mechlorethamine (and other compo-
nents of MOPP- and MOPP-like regimens) were highly correlated
(of 1.864 patients treated with procarbazine, 131 (7.0%) did not
receive mechlorethamine, while procarbazine and mechloretha-
mine dose-groups were discordant for only 52 (2.8%) patients), we
could not disentangle the effects of both drugs. We attribute the
observed increased risk to procarbazine in presentation of our
results because procarbazine is given orally and possibly comes in
direct contact with colon mucosa and has been implicated in
stomach carcinogenesis in previous papers van (van den Belt-
Dusebout et al, 2009; Morton et al, 2013).
In accordance with other studies of second solid malignancy risk
among HL patients, in our study, CRC relative risk was higher for
patients treated at younger ages (Swerdlow et al, 2000; Dores et al,
2002; Hodgson et al, 2007; Schaapveld et al, 2015). However, when
evaluating colon and rectum separately, the SIR of rectal cancer
was not much affected by age, while colon cancer risk behaved
more in line with a radiation-associated pattern, such as observed
for breast (van Leeuwen et al, 2000), lung (Swerdlow et al, 2000)
and stomach (van den Belt-Dusebout et al, 2009) cancer, also
showing the highest SIRs among patients exposed to radiation at
the very young ages.
Strengths of our study are the large size of the cohort, the
detailed information on HL treatment and the long and complete
follow-up for second malignancies. However, despite the large size
of our cohort, the number of CRC cases was still rather low for a
detailed assessment of the association of HL treatment and
subsequent CRC risk. Given the large number of comparisons
made in our paper we caution against over-interpretation of our
findings, especially when based on small number of events. We had
no information on common risk factors for CRC such as family
history of CRC.
Surveillance bias is an unlikely explanation for the increased
CRC risk in our study, as there have been no CRC surveillance
recommendations in HL survivors. Furthermore, CRC screening in
the Dutch general population was only introduced in January 2014.
Since HL patients nowadays only rarely receive high-dose
procarbazine in combination with infradiaphragmatic radiother-
apy, we expect that CRC risk following HL will decrease. Although
most patients in our cohort were treated decades ago, often with
treatment regimens now considered outdated, evaluation of long-
term effects of these treatments remains relevant and our findings
have important implications for HL patients treated in the past.
Since HL predominantly occurs at young ages, the cohort of HL
survivors treated in the 1960s–1980s has only recently reached the
ages at which CRC commonly occurs in the general population.
Importantly, our data do not show that CRC risk levels off after
longer follow-up duration. When considering more intensive CRC
surveillance in HL survivors we must realise, however, that we do
not know whether the pathogenesis of treatment-induced CRC in
HL survivors is similar to that of CRC in the general population.
As in the general population, most CRCs among HL survivors were
adenocarcinomas and it appears that treatment-induced CRCs are
preceded by adenomas as well (Rigter et al, 2016; Rigter et al,
2017). Currently, most screening guidelines for HL survivors do
not yet include CRC screening. The Children’s Oncology Group
does recommend that childhood cancer survivors exposed to
430Gy of abdominal radiation have a colonoscopy at least every 5
years, starting at the age of 35, or 10 years after radiation,
whichever occurs last (Children’s Oncology Group, 2008). On the
basis of our results, also in view of the unfavourable stage
distribution and low 5-year overall survival rate, we think that CRC
surveillance should be considered in HL survivors who received
high-dose procarbazine and infradiaphragmatic radiation therapy,
starting 10 years after first treatment but not before the age of 35
years.
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